title: Plasma adropin levels predict endothelial dysfunction like flow-mediated dilatation in patients with type 2 diabetes mellitus.
abstract: OBJECTIVE
  This study investigated the role of plasma adropin levels to show endothelial dysfunction in individuals with type 2 diabetes mellitus and to compare these with flow-mediated dilatation.
  
  
  METHODS
  A total of 92 individuals with diagnosed type 2 diabetes mellitus were included and divided into 2 groups according to their brachial flow-mediated dilatation. The endothelial dysfunction group consisted of 46 participants with flow-mediated dilatation change of less than 7%, whereas 46 participants with flow-mediated dilatation change of more than 7% were accepted as the nonendothelial dysfunction group. Venous blood samples were taken from all study participants, and plasma adropin levels were measured using an enzyme-linked immunosorbent assay kit.
  
  
  RESULTS
  The mean flow-mediated dilatation values were 13.2% ± 4.9% in the nonendothelial dysfunction group, and 3.5% ± 3.4% in the endothelial dysfunction group. Mean hemoglobin A1c levels were significantly higher in the endothelial dysfunction group than in the nonendothelial dysfunction group (8.7% ± 1.9% vs 7.9% ± 1.6%, respectively; P < 0.038). Mean plasma adropin levels were 3.04 ± 0.79 ng/mL in the endothelial dysfunction group and 4.67 ± 1.43 ng/mL in the nonendothelial dysfunction group; P < 0.001. Plasma adropin levels showed no correlation with body mass index (r = -0.072, P = 0.497) but were positively correlated with flow-mediated dilatation values (r = 0.537, P < 0.001). In the linear regression analysis, adropin and hemoglobin A1c were independent risk factors for endothelial dysfunction in individuals with type 2 diabetes mellitus.
  
  
  CONCLUSIONS
  Adropin is a new marker for use in demonstrating endothelial dysfunction.
authors.affiliation: From the *Department of Cardiology, Turhal State Hospital, Tokat, Turkey; †Department of Cardiology, Mersin University Medical Faculty, Mersin, Turkey; ‡Departments of Microbiology, and §Internal Medicine, Turhal State Hospital, Tokat, Turkey; ∥Department of Cardiovascular Surgery, Elazig Education and Research Hospital, Elazig, Turkey; and ¶Department of Biochemistry, Firat University Medical Faculty, Elazig, Turkey.
authors.forename: Mustafa
authors.initials: M
authors.lastname: Topuz
authors.forename: Ahmet
authors.initials: A
authors.lastname: Celik
authors.forename: Tutku
authors.initials: T
authors.lastname: Aslantas
authors.forename: Ayse Kevser
authors.initials: AK
authors.lastname: Demir
authors.forename: Suna
authors.initials: S
authors.lastname: Aydin
authors.forename: Suleyman
authors.initials: S
authors.lastname: Aydin
mesh_terms: D015415:Biomarkers / Q000097:blood; D001783:Blood Flow Velocity / Q000502:physiology*; D001798:Blood Proteins / Q000378:metabolism*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000175:diagnosis; D004730:Endothelium, Vascular / Q000378:metabolism*; D005260:Female; D006801:Humans; D036341:Intercellular Signaling Peptides and Proteins; D008297:Male; D008875:Middle Aged; D010455:Peptides; D011237:Predictive Value of Tests; D011446:Prospective Studies; D014664:Vasodilation / Q000502:physiology*
chemical_list: D015415:Biomarkers; D001798:Blood Proteins; C568440:Enho protein, human; D036341:Intercellular Signaling Peptides and Proteins; D010455:Peptides